Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Lymphoma, Leukemia & Myeloma Network

Featured

Samantha Shenoy
Videos
Management Considerations for Oral Toxicities Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
05/10/2024
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses...
05/10/2024
Lymphoma, Leukemia & Myeloma Network
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/19/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD, Weill Cornell Medicine
Conference Coverage
Evaluating Recent Study Findings on Treatment Combinations for Patients With MCL
04/19/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jia Ruan, MD, PhD, shares expert insight regarding recent and ongoing studies on treatment combinations for elderly and/or high-risk patients with mantle cell lymphoma.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jia Ruan, MD, PhD, shares expert insight regarding recent and ongoing studies on treatment combinations for elderly and/or high-risk patients with mantle cell lymphoma.
At the 2024 Great Debates &...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD, Weill Cornell Medicine
Conference Coverage
Assessing Novel Non-Chemotherapy Agents as Initial Therapeutic Options for Patients With Mantle Cell Lymphoma
04/19/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the 2024 Great Debates and Updates in Hematological Malignancies Meeting, Jia Ruan, MD, PhD, discusses the emergence of novel non-chemotherapy agents as initial therapeutic options for patients with mantle cell lymphoma, focusing on the...
At the 2024 Great Debates and Updates in Hematological Malignancies Meeting, Jia Ruan, MD, PhD, discusses the emergence of novel non-chemotherapy agents as initial therapeutic options for patients with mantle cell lymphoma, focusing on the...
At the 2024 Great Debates and...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Clinical Trials for Treatment Data in Hodgkin Lymphoma Research
04/18/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, emphasizes the importance of continuing clinical trials for patients with Hodgkin lymphoma to gather valuable treatment data.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, emphasizes the importance of continuing clinical trials for patients with Hodgkin lymphoma to gather valuable treatment data.
At the 2024 Great Debates &...
04/18/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Individualized Therapy, Prognostication, and Prediction in the Treatment of Hodgkin Lymphoma
04/16/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates &...
04/16/2024
Oncology
From Oncology
Brea Lipe, University of Rochester Medical Center
Conference Coverage
Should the Sequencing of BCMA-Directed Therapy be Used in Multiple Myeloma Treatment?
04/16/2024

Featuring Brea Lipe, MD

Featuring Brea Lipe, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates &...
04/16/2024
Oncology
From Oncology
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Ashley Rosko, MD
Conference Coverage
Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting
04/10/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center
Conference Coverage
Recent Updates in Risk Stratification and Treatment Methods for Patients With MDS
04/10/2024

Featuring Aditi Shastri, MD

Featuring Aditi Shastri, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Aditi Shastri, MD, shares expert insight on recent updates in risk stratification and treatment regimens for patients with low to intermediate risk myelodysplastic...
During the 2024 Great Debates &...
04/10/2024
Oncology
From Oncology

Advertisement

Interactive Features

Quiz
Overall Response Rate of Tafasitamab Plus Lenalidomide for Patients With R/R Diffuse Large B-Cell Lymphoma
06/14/2023
Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?
Quiz: According to final results of the phase 2 L-MIND study, what was the overall response rate of tafasitamab plus lenalidomide followed by long-term tafasitamab monotherapy for patients with R/R diffuse large B-cell lymphoma?
Quiz: According to final results...
06/14/2023
Oncology
Quiz
Radiomics Features and Prediction of Outcomes for Aggressive B-Cell Lymphoma
06/09/2023
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study assessing the predictive quality of clinical, molecular genotype, and radiomics features for aggressive B-cell lymphoma, results indicated that radiomics features extracted from baseline 18F-FDG PET/CT scans...
True or False In a study...
06/09/2023
Oncology

Insights

Samantha Shenoy
Videos
Management Considerations for Oral Toxicities Associated With Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
05/10/2024
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses considerations for nurses and advanced practitioners managing patients with relapsed/refractory multiple myeloma experiencing oral toxicities after treatment with talquetamab.
Samantha Shenoy, NP, discusses...
05/10/2024
Lymphoma, Leukemia & Myeloma Network
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/19/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD, Weill Cornell Medicine
Conference Coverage
Evaluating Recent Study Findings on Treatment Combinations for Patients With MCL
04/19/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jia Ruan, MD, PhD, shares expert insight regarding recent and ongoing studies on treatment combinations for elderly and/or high-risk patients with mantle cell lymphoma.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jia Ruan, MD, PhD, shares expert insight regarding recent and ongoing studies on treatment combinations for elderly and/or high-risk patients with mantle cell lymphoma.
At the 2024 Great Debates &...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Jia Ruan, MD, PhD, Weill Cornell Medicine
Conference Coverage
Assessing Novel Non-Chemotherapy Agents as Initial Therapeutic Options for Patients With Mantle Cell Lymphoma
04/19/2024

Featuring Jia Ruan, MD, PhD

Featuring Jia Ruan, MD, PhD
At the 2024 Great Debates and Updates in Hematological Malignancies Meeting, Jia Ruan, MD, PhD, discusses the emergence of novel non-chemotherapy agents as initial therapeutic options for patients with mantle cell lymphoma, focusing on the...
At the 2024 Great Debates and Updates in Hematological Malignancies Meeting, Jia Ruan, MD, PhD, discusses the emergence of novel non-chemotherapy agents as initial therapeutic options for patients with mantle cell lymphoma, focusing on the...
At the 2024 Great Debates and...
04/19/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Clinical Trials for Treatment Data in Hodgkin Lymphoma Research
04/18/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, emphasizes the importance of continuing clinical trials for patients with Hodgkin lymphoma to gather valuable treatment data.
At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Evens, DO, MBA, MSc, emphasizes the importance of continuing clinical trials for patients with Hodgkin lymphoma to gather valuable treatment data.
At the 2024 Great Debates &...
04/18/2024
Lymphoma, Leukemia & Myeloma Network
Andrew Evens, DO, MBA, MSc, Rutgers Cancer Institute of New Jersey
Conference Coverage
Importance of Individualized Therapy, Prognostication, and Prediction in the Treatment of Hodgkin Lymphoma
04/16/2024

Featuring Andrew Evens, DO, MBA, MSc

Featuring Andrew Evens, DO, MBA, MSc ...
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Andrew Evens, DO, MBA, MSc, speaks on the importance of targeted therapy, prognostication, and prediction when treating patients with Hodgkin lymphoma.
During the 2024 Great Debates &...
04/16/2024
Oncology
Brea Lipe, University of Rochester Medical Center
Conference Coverage
Should the Sequencing of BCMA-Directed Therapy be Used in Multiple Myeloma Treatment?
04/16/2024

Featuring Brea Lipe, MD

Featuring Brea Lipe, MD
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Brea Lipe, MD, argues against the utilization of sequencing BCMA-directed therapies as a treatment regimen for patients with multiple myeloma.
During the 2024 Great Debates &...
04/16/2024
Oncology
John Allan, MD, Weill Cornell Medicine
Conference Coverage
Comparing BTK Inhibitors for Frontline Chronic Lymphocytic Leukemia Treatment
04/10/2024

Featuring John Allan, MD

Featuring John Allan, MD
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use of different BTK inhibitors for the treatment of CLL in a frontline setting and discusses whether there is an optimal drug regimen to use among patients with CLL.
John Allan, MD, compares the use...
04/10/2024
Lymphoma, Leukemia & Myeloma Network
Ashley Rosko, MD
Conference Coverage
Factors to Consider When Treating Patients With Multiple Myeloma With Bispecific Antibodies in an Outpatient Setting
04/10/2024

Featuring Ashley Rosko, MD

Featuring Ashley Rosko, MD
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses factors to consider when administering bispecific antibody therapy to patients with multiple myeloma in an outpatient setting, which she discussed at the 2024 Great Debates & Updates in Hematologic Malignancies...
Ashley Rosko, MD, discusses...
04/10/2024
Lymphoma, Leukemia & Myeloma Network

Meeting Materials

The Tree That Hides the Forest: An Unfortunate Story of T/NK Lymphoma
Introduction: NK/T lymphoma is a rare type of non-Hodgkin's lymphoma [1,2]. It is a clinical entity that manifests itself essentially by a necrosis that usually starts in the nasal caviti...
11/04/2022
Real-world Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): IONA-MM First Interim Analysis
Introduction:
11/04/2022
Developing an Ontology-Based Platform to Detect Serine Protease Involvement in BALT Lymphoma Patients with COVID-19 & Connect Them to Clinical Trials
Introduction:
11/04/2022

Advertisement

Advertisement

In the News

News
Circulating Tumor DNA Monitoring for Patients With Follicular Lymphoma Undergoing CAR T-Cell Therapy
06/26/2023

Jordan Kadish 

Jordan Kadish 
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring...
06/26/2023
Oncology
News
Efficacy and Safety of Rituximab-Bendamustine vs R-CHOP Among Patients With Follicular Lymphoma
06/26/2023

Jordan Kadish

Jordan Kadish
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and...
06/26/2023
Oncology
News
FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
06/23/2023

Jordan Kadish

Jordan Kadish
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA...
06/23/2023
Oncology
News
Brentuximab Vedotin Plus Doxorubicin and Dacarbazine for Patients With Nonbulky Limited-Stage Classic Hodgkin Lymphoma
06/23/2023

Jordan Kadish

Jordan Kadish
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study...
06/23/2023
Oncology
News
Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL
06/08/2023

Jordan Kadish

Jordan Kadish
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
Ki67 Expression Shows Promise as a Predictive Marker for Follicular Lymphoma
06/08/2023

Jordan Kadish

Jordan Kadish
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression...
06/08/2023
Oncology

Advertisement

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use